Wockhardt Limited (NSE:WOCKPHARMA) — Market Cap & Net Worth
Market Cap & Net Worth: Wockhardt Limited (WOCKPHARMA)
Wockhardt Limited (NSE:WOCKPHARMA) has a market capitalization of $3.63 Billion (Rs335.40 Billion) as of September 16, 2026. Listed on the NSE stock exchange, this India-based company holds position #4372 globally and #191 in its home market, demonstrating a -1.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wockhardt Limited's stock price Rs2064.10 by its total outstanding shares 162492169 (162.49 Million). Also see Wockhardt Limited balance sheet assets for a full breakdown of the balance sheet.
Wockhardt Limited Market Cap History: 2015 to 2026
Wockhardt Limited's market capitalization history from 2015 to 2026. Data shows growth from $2.44 Billion to $3.63 Billion (3.41% CAGR). Also see Wockhardt Limited cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Wockhardt Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$151.69 Billion | 2.39% | #2 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.13 Trillion | 0.12% | #173 of 750 |
Weight: Wockhardt Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Wockhardt Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wockhardt Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Wockhardt Limited for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.08x
Wockhardt Limited's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.07 Billion | $44.53 Billion | $2.51 Billion | 0.02x | 0.42x |
| 2017 | $1.51 Billion | $39.66 Billion | -$1.96 Billion | 0.04x | N/A |
| 2018 | $847.63 Million | $39.24 Billion | -$6.08 Billion | 0.02x | N/A |
| 2019 | $378.98 Million | $35.66 Billion | -$1.95 Billion | 0.01x | N/A |
| 2020 | $885.38 Million | $28.44 Billion | -$692.20 Million | 0.03x | N/A |
| 2021 | $668.79 Million | $27.08 Billion | $6.86 Billion | 0.02x | 0.10x |
| 2022 | $391.96 Million | $32.30 Billion | -$2.44 Billion | 0.01x | N/A |
| 2023 | $745.71 Million | $26.57 Billion | -$5.59 Billion | 0.03x | N/A |
| 2024 | $2.49 Billion | $28.30 Billion | -$4.63 Billion | 0.09x | N/A |
| 2025 | $2.54 Billion | $30.35 Billion | -$470.00 Million | 0.08x | N/A |
Competitor Companies of WOCKPHARMA by Market Capitalization
Companies near Wockhardt Limited in the global market cap rankings as of September 16, 2026. Review WOCKPHARMA tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Wockhardt Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Wockhardt Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Wockhardt Limited's market cap moved from $2.44 Billion to $ 3.63 Billion, with a yearly change of 3.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs3.63 Billion | +42.73% |
| 2025 | Rs2.54 Billion | +2.07% |
| 2024 | Rs2.49 Billion | +233.89% |
| 2023 | Rs745.71 Million | +90.25% |
| 2022 | Rs391.96 Million | -41.39% |
| 2021 | Rs668.79 Million | -24.46% |
| 2020 | Rs885.38 Million | +133.62% |
| 2019 | Rs378.98 Million | -55.29% |
| 2018 | Rs847.63 Million | -43.82% |
| 2017 | Rs1.51 Billion | +41.60% |
| 2016 | Rs1.07 Billion | -56.38% |
| 2015 | Rs2.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Wockhardt Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.63 Billion USD |
| MoneyControl | $3.63 Billion USD |
| MarketWatch | $3.63 Billion USD |
| marketcap.company | $3.63 Billion USD |
| Reuters | $3.63 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more